Loading
IARC estimates 16,448 new cancer cases and 8,789 cancer deaths in Uruguay in 2024; the commonest new cancers are breast, colorectum and trachea, bronchus and lung. This page is assembled automatically from OnCo's data: 1 institution and 1 person, and says what OnCo does not yet hold.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Breast | 2,212 | 76.3 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Colorectum | 2,156 | 32.3 | Colorectal cancer |
| Trachea, bronchus and lung | 1,723 | 28.7 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Prostate | 1,608 | 57.5 | Prostate cancer |
| Kidney | 770 | 13.9 | Renal cell carcinoma |
| Pancreas | 766 | 10.7 | Pancreatic ductal adenocarcinoma |
| Bladder | 591 | 8.7 | Bladder & urothelial cancer |
| Stomach | 566 | 8.7 | Gastric & gastro-oesophageal junction cancer |
| Non-Hodgkin lymphoma | 522 | 9.1 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Cervix uteri | 378 | 16.3 | Cervical cancer |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Trachea, bronchus and lung | 1,501 | 24.3 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Colorectum | 1,091 | 13.9 | Colorectal cancer |
| Breast | 776 | 21.4 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Pancreas | 691 | 9.5 | Pancreatic ductal adenocarcinoma |
| Prostate | 583 | 16.2 | Prostate cancer |
| Stomach | 416 | 6.0 | Gastric & gastro-oesophageal junction cancer |
| Kidney | 315 | 4.6 | Renal cell carcinoma |
| Bladder | 272 | 3.2 | Bladder & urothelial cancer |
| Oesophagus | 250 | 3.7 | Oesophageal cancer |
| Non-Hodgkin lymphoma | 239 | 3.5 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
No trial record in OnCo lists a site in Uruguay. OnCo reads sites from ClinicalTrials.gov; studies registered only elsewhere are searchable through the WHO International Clinical Trials Registry Platform.
People whose main affiliation in OnCo is an institution or company in Uruguay.
OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Uruguay is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.
Uruguay is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.